| Entry |
|
|---|
| Name |
Buprenorphine (JAN/INN);
Temgesic (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C29H41NO4
|
|---|
| Exact mass |
467.3036
|
|---|
| Mol weight |
467.6401
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Analgesic
DG01984 Opioid analgesics
DG01586 Opioid receptor antagonist
Other
DG01718 Drugs for addictive disorder
DG01717 Drugs for opioid dependence
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 1149 |
| Product (DG00820): | D07132<JP/US> D00836<JP/US> |
| Product (mixture): | D10250<US> |
|
|---|
| Efficacy |
Analgesic, Opioid receptor agonist/antagonist |
|---|
| Comment |
Morphinan derivative, Oripavine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07224 | Opioid receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02A OPIOIDS
N02AE Oripavine derivatives
N02AE01 Buprenorphine
D07132 Buprenorphine (JAN/INN) <JP/US>
N07 OTHER NERVOUS SYSTEM DRUGS
N07B DRUGS USED IN ADDICTIVE DISORDERS
N07BC Drugs used in opioid dependence
N07BC01 Buprenorphine
D07132 Buprenorphine (JAN/INN) <JP/US>
USP drug classification [BR:br08302]
Analgesics
Opioid Analgesics, Long-acting
Buprenorphine
D07132 Buprenorphine (JAN/INN)
Anti-Addiction/Substance Abuse Treatment Agents
Opioid Dependence Treatments
Buprenorphine
D07132 Buprenorphine (JAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
114 Antipyretics and analgesics, anti-inflammatory agents
1149 Others
D07132 Buprenorphine (JAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Opioid
OPRM1
D07132 Buprenorphine (JAN/INN) <JP/US>
OPRK1
D07132 Buprenorphine (JAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07132
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D07132
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07132
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 34
1 C1z C 16.5998 -15.1247
2 C1z C 17.7863 -15.8227
3 C1y C 15.4132 -15.8227
4 C8y C 16.5998 -13.7986
5 C1x C 17.7863 -14.4267
6 C1y C 18.9729 -15.1247
7 C1x C 17.7863 -17.2186
8 C1x C 17.2280 -16.8697
9 C1z C 15.4132 -17.1488
10 O2x O 14.7851 -14.2872
11 C8y C 15.4830 -13.1006
12 C8y C 17.8561 -13.1006
13 C1x C 20.1595 -14.4267
14 N1y N 20.1595 -15.8227
15 C1x C 18.9727 -13.7986
16 C1y C 16.5998 -17.8468
17 C1x C 16.0414 -16.1717
18 C8y C 15.4830 -11.7047
19 C8x C 17.8561 -11.7047
20 C1b C 21.3460 -15.1945
21 C8x C 16.6696 -11.0067
22 O1a O 14.2965 -11.0067
23 C1y C 22.5326 -15.8925
24 C1x C 23.2305 -17.0790
25 C1x C 23.9285 -15.8925
26 O2a O 14.0173 -17.1488
27 C1a C 13.3193 -15.9400
28 C1d C 17.2978 -19.0557
29 C1a C 18.6935 -19.0557
30 C1d C 16.6094 -20.2477
31 O1a O 17.9861 -20.2478
32 C1a C 15.2041 -20.2478
33 C1a C 17.2930 -21.4316
34 C1a C 15.7619 -21.4443
BOND 40
1 1 5 1 #Up
2 2 6 1
3 2 7 1
4 2 8 1 #Down
5 3 9 1
6 3 10 1 #Down
7 4 11 1
8 4 12 2
9 5 13 1
10 6 14 1 #Up
11 6 15 1
12 7 16 1
13 8 17 1
14 11 18 2
15 12 19 1
16 14 20 1
17 18 21 1
18 18 22 1
19 9 16 1
20 9 17 1 #Down
21 10 11 1
22 12 15 1
23 14 13 1 #Up
24 19 21 2
25 1 2 1
26 20 23 1
27 1 3 1
28 1 4 1
29 23 24 1
30 23 25 1
31 25 24 1
32 9 26 1
33 26 27 1
34 16 28 1
35 28 29 1 #Up
36 28 30 1
37 28 31 1 #Down
38 30 32 1
39 30 33 1
40 30 34 1
|
|---|
